Colistin-Induced Acute Kidney Injury and the Effect on Survival in Patients with Multidrug-Resistant Gram-Negative Infections: Significance of Drug Doses Adjusted to Ideal Body Weight
Open Access
- 20 December 2021
- journal article
- research article
- Published by Wiley in International Journal of Nephrology
- Vol. 2021, 1-12
Abstract
Background. Colistin is a lifesaving treatment for multidrug-resistant Gram-negative bacterial (MDR-GNB) infections along with its well-known nephrotoxicity. The controversy of colistin-induced acute kidney injury (AKI) on mortality is noted. This study aimed to determine the risk factors and impact of AKI on the survival and significance of colistin dosage. Methods. A retrospective cohort study was performed in adult patients who received intravenous colistin for MDR-GNB treatment between June 2015 and June 2017. Factors influencing colistin-induced AKI and survival were evaluated by Cox regression analysis. Cut-off levels of the colistin dose per ideal body weight (IBW) that significantly affected clinical outcomes were assessed with linearity trends and receiver operating characteristic analyses. Results. AKI occurred in 68.5% of 412 enrolled patients with an incidence rate of 10.6 per 100 patients-days and a median time was 6 (3–13) days. Stages I–III of AKI were 38.3, 24.5, and 37.2%. Factors associated with colistin-induced AKI were advanced age, high serum bilirubin, AKI presented before colistin administration, increased daily colistin doses per IBW, and concomitant use of nephrotoxic drugs. Colistin-induced AKI was related to mortality (HR 1.74, 95% CI 1.06–2.86, ). In the non-AKI before colistin usage subgroup, the total dose and total dose/IBW were >1,500–2,000 mg and 30–35 mg/kg to benefit mortality reduction but were 4.5 mg/kg/day also increased the risk of AKI. In the AKI developed before colistin subgroup, the cut-off values of total colistin dose >1250–1350 mg and total dose/IBW >23.5–24 mg/kg demonstrated significant risks of AKI. Conclusion. The incidence of AKI after colistin administration was high and impacted mortality. Prevention and early correction of these related factors are mandatory. Careful use of colistin was also both beneficial in mortality and AKI reductions.Keywords
Funding Information
- Thailand Science Research and Innovation (C10F630030)
- National Research Council of Thailand (C10F630030)
This publication has 52 references indexed in Scilit:
- Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective studyBMC Anesthesiology, 2013
- Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort studyBMC Infectious Diseases, 2013
- Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyCritical Care, 2013
- Nephrotoxicity Associated with Intravenous Colistin in Critically Ill PatientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health SystemClinical Infectious Diseases, 2011
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of PatientsAntimicrobial Agents and Chemotherapy, 2011
- Risk factors for colistin-associated nephrotoxicityJournal of Infection, 2011
- Colistin Dosing and Nephrotoxicity in a Large Community Teaching HospitalAntimicrobial Agents and Chemotherapy, 2010
- Renal dysfunction in chronic liver diseaseCritical Care, 2010
- Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical CenterClinical Infectious Diseases, 2009